Business
VYNE Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
Conference Call Today at 8:30am Eastern Time BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the
About this update from Vyne Therapeutics Inc.
[{"type":"text","content":"Conference Call Today at 8:30am Eastern Time\nBRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update.\n “The launch of ZILXI™ on October 1st means that VYNE now has two commercial products in the dermatology market. Our immediate priorities for ZILXI are to leverage our sales organization and physician experience with AMZEEQ® to drive rapid uptake, and to gain broad payor acceptance and reimbursement,” said David Domzalski, Chief Executive Officer of VYNE. “For AMZEEQ, we are pleased to see that prescriptions have eclipsed pre-COVID levels for the first time since the shut down in March and that the overall market in acne continues to recover.” Third Quarter and Recent highlights: Changed corporate name to VYNE Therapeutics Inc. and our ticker to \"VYNE,\" effective September 8, 2020.ZILXI (minocycline) topical foam, 1.5% for the treatment of inflammatory lesions of rosacea in adults launched and was available in pharmacies nationwide on October 1st. First minocycline product of any form to be approved by the FDA for use in rosacea.Express Scripts elected to cover ZILXI effective October 2, 2020 on its National Preferred, Flex, and Basic commercial formularies. AMZEEQ (minocycline) topical foam, 4% for the treatment of inflammatory lesions of moderate to severe acne vulgaris in adults and patients 9 years of age and older continues to gain market share in acne. Prescription volume in Q3 2020 was 32,734, representing 52% growth from Q2 2020. Market recovery in acne continues and overall script counts continue to grow. Hosted Investor Event: Physician Symposium on October 1st which highlighted the way in which dermatologists use AMZEEQ and plan to use ZILXI in their practices. Presenting dermatologists were pleased with the performance of AMZEEQ for their patients and expect to see broad use in acne, and believe ZILXI can quickly become their first in line therapy for rosacea.A replay of the event can be accessed on the VYNE Therapeutics website here. End of Phase 2 meeting scheduled in Q4 for FCD105.Appointed Mr. Patrick G. LePore to serve as a director of the Company. Mr. LePore brings more than 40 years of experience in the pharmaceutical industry, in both...